Nancy Simonian

2021

In 2021, Nancy Simonian earned a total compensation of $3.1M as President & Chief Executive Officer at Syros Pharmaceuticals, a 23% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$322,905
Option Awards$2,163,749
Salary$615,923
Other$576
Total$3,103,153

Simonian received $2.2M in option awards, accounting for 70% of the total pay in 2021.

Simonian also received $322.9K in non-equity incentive plan, $615.9K in salary and $576 in other compensation.

Rankings

In 2021, Nancy Simonian's compensation ranked 4,301st out of 12,415 executives tracked by ExecPay. In other words, Simonian earned more than 65.4% of executives.

ClassificationRankingPercentile
All
4,301
out of 12,415
65th
Division
Manufacturing
1,776
out of 5,505
68th
Major group
Chemicals And Allied Products
744
out of 2,375
69th
Industry group
Drugs
664
out of 2,096
68th
Industry
Pharmaceutical Preparations
471
out of 1,546
70th
Source: SEC filing on April 21, 2022.

Simonian's colleagues

We found three more compensation records of executives who worked with Nancy Simonian at Syros Pharmaceuticals in 2021.

2021

Jason Haas

Syros Pharmaceuticals

Chief Financial Officer

2021

David Roth

Syros Pharmaceuticals

Chief Medical Officer

2021

Eric Olson

Syros Pharmaceuticals

Chief Scientific Officer

News

In-depth

You may also like